Janssen

TECVAYLI

Manufacturer:

Janssen

Tecvayli HCPCS:

C9148

HCPCS Code Descriptor:

Injection, teclistamab-cqyv, 0.5 mg

Category:

C Code

Tecvayli NDCs:

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Route of Administration:

Subcutaneous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Tecvayli:

TECVAYLI is an Oncology drug manufactured by Janssen and administered via the Subcutaneous route of administration. The C Code: C9148 is aligned to the drug TECVAYLI.

ACCESS PRICING AND MORE BY REGISTERING

C9148 Added Date:

April 1, 2023

C9148 Effective Date:

July 1, 2023

C9148 Termination Date:

June 30, 2023

We have not yet identified a manufacturer source of Tecvayli billing and coding information.
Tecvayli patient assistance information can be found through Janssen CarePath at the URL: https://www.janssencarepath.com/patient/tecvayli/cost-support
TECVAYLI prescribing information can be found at the link below:
Information regarding TECVAYLI’s side effects can be found at MedlinePlus